Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 12

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 12
---
 issuance pursuant to the 2021 Plan; and                                            |
| ● | 1,780,159  shares of common                                                                                            
 stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $29.14 per share; and |
| ● | 190,795 shares of common stock issuable upon the exercise of pre-funded                                                
 warrants outstanding at an exercise price of $0.01 per share.                                                          |

Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to:

| ● | no                                                                                                                                       
 exercise of the options or warrants described above;                                                                                     |
| ● | no                                                                                                                                       
 sale of any pre-funded warrants in this offering, which, if sold, would reduce the number of shares of common stock that we are offering 
 on a one-for-one basis;                                                                                                                  |
| ● | no                                                                                                                                       
 exercise of any common warrants issued in this offering; and                                                                             |
| ● | no                                                                                                                                       
 exercise of any Placement Agent Warrants to be issued to the Placement Agent or its designees as compensation in connection with         
 this offering.                                                                                                                           |

| 5 |

<div align='center'>rISK FACTORS</div>

Investing in our securities involves a high degree of risk. You should carefully consider the risks described below and the risks described in our most recent Annual Report on Form 10-K, which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment.

<div align='center'>Risks Related to the Offering</div>

You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.

Since
the effective price per share of our common stock being offered is substantially higher than the net tangible book value per share of
our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering.
Based on the assumed combined public offering price of $6.40 per share of common stock and